ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AIDA AIDA Pharmaceuticals Inc (CE)

0.0003
0.00 (0.00%)
05 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
AIDA Pharmaceuticals Inc (CE) USOTC:AIDA OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0003 0.00 00:00:00

Aida Pharmaceuticals Inc - Current report filing (8-K)

01/04/2008 6:26pm

Edgar (US Regulatory)


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 8-K


CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 1, 2008


AIDA PHARMACEUTICALS, INC.

 (Exact name of registrant as specified in its charter)


 

 

 

Nevada

(State or other jurisdiction of incorporation)

000-50212

(Commission

File Number)

81-0592184

(IRS Employer

Identification No.)


 

 

31 Dingjiang Road, Jianggan District

Hangzhou, China

(Address of principal executive offices)

310016

(Zip Code)


Registrant’s telephone number, including area code: 86-0571-85802712


Copies to:

Richard Friedman, Esq.

Benjamin Tan, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32 Floor

New York, New York 10006

Phone: (212) 930-9700

Fax: (212) 930-9725


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))











Item 9.01

Financials Statements and Exhibits


(d)


Exhibit No.

Exhibit Description


99.1

Press Release dated April 1, 2008



SIGNATURES


Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



AIDA PHARMACEUTICALS, INC.



Dated: April 1, 2008

By:  /s/  Biao Jin                           

Name: Biao Jin

Title:   Chief Executive Officer







1 Year AIDA Pharmaceuticals (CE) Chart

1 Year AIDA Pharmaceuticals (CE) Chart

1 Month AIDA Pharmaceuticals (CE) Chart

1 Month AIDA Pharmaceuticals (CE) Chart

Your Recent History

Delayed Upgrade Clock